ArticleTranslational lung cancer research2026
Real-world insights into multidisciplinary management and outcomes of stage III (N2-3) non-small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stage III (N2-3) non-small cell lung cancer (NSCLC) represents a highly heterogeneous group, with limited evidence to guide multidisciplinary management in real-world settings. This study aimed to evaluate treatment patterns and associated pathological and survival outcomes in this population. Methods: This study analyzed patients with stage III (N2-3) NSCLC treated at our center between 2009 and 2024. All patients had pathologically confirmed mediastinal lymph node involvement and received neoadjuvant therapy. Treatment patterns, pathological responses, and survival outcomes were systematically assessed. Survival was estimated using the Kaplan-Meier method, and prognostic factors were identified with Cox regression analyses. Results: A total of 243 eligible patients were included. Treatment allocation was stratified by oncogenic driver status, with 75 receiving neoadjuvant immunotherapy-chemotherapy (IO-chemo), 46 targeted therapy, and 122 chemotherapy. Following neoadjuvant treatments, 175 patients (72.0%) underwent surgical resection, 46 (18.9%) received radiotherapy, and 22 (9.1%) continued systemic therapy. The IO-chemo group had the most surgical patients (77.3%) and demonstrated superior pathological responses among resected cases, with pathological complete response (pCR) and major pathological response (MPR) rates of 34.5% and 48.3%, respectively. Median event-free survival (EFS) and overall survival (OS) for the entire cohort were 28.7 months and 67.2 months. Patients treated with chemotherapy had worse survival compared with those treated with IO-chemo and targeted therapy, while survival outcomes were similar between the latter two groups. Multivariate analysis identified neoadjuvant IO-chemo as an independent favorable factor for both EFS and OS. At last, maintenance therapy following surgery or radiotherapy was associated with improved survival. Conclusions: In this real-world cohort of stage III (N2-3) NSCLC, novel neoadjuvant therapies, including IO-chemo and targeted therapy, achieved superior pathological responses and improved survival compared with chemotherapy. Importantly, even patients with N3 disease derived meaningful benefit from surgery when combined with effective neoadjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.